Targeting mutated GTPase KRAS in tumor therapies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34520956/

Kirsten rat sarcoma virus oncogene (KRAS) mutation accounts for approximately 85% of RAS-driven cancers, and participates in multiple signaling pathways and mediates cell proliferation, differentiation and metabolism. KRAS has been considered as an "undruggable" target due to the lack of effective d ...